Two Year Outcomes of a Multicenter, Prospective Pilot Study of Gamma Knife Radiosurgery for Mesial Temporal Lobe Epilepsy: Seizure Remission and Morbidity
Abstract number :
A.02
Submission category :
Clinical Epilepsy-Adult
Year :
2006
Submission ID :
6061
Source :
www.aesnet.org
Presentation date :
12/1/2006 12:00:00 AM
Published date :
Nov 30, 2006, 06:00 AM
Authors :
1Mark Quigg, 2Nicholas M. Barbaro, 3Kenneth D. Laxer, 2Marianne L. Ward, and Epilepsy Radiosurgery Study Group
Gamma Knife radiosurgery (GKS) offers an alternative to open surgery for mesial temporal lobe epilepsy (MTLE), but its safety and efficacy are not well-established. We report the two year outcome on seizure remission and morbidities of a multicenter, prospective pilot study of GKS., Patients had unilateral MTLE as determined by standard presurgical evaluation. GKS, randomized to 20 Gy or 24 Gy comprising 5.0-7.5mL at the 50% isodose volume, was performed on mesial structures including the amygdala, hippocampus, and parahippocampal gyrus. Treatment plans were approved at a central site to insure uniformity of lesions. Patients and primary treating physicians were blinded to dose. Regular visits with seizure diaries were obtained for 3 months at presurgical baseline and postoperatively for every three months until 18m, then at 24m. Patients were counted as [ldquo]seizure-free[rdquo] if no seizures (excluding auras) occurred between visits 18m-24m. Any subject that was not available for analysis was considered not seizure-free., Of 40 planned enrollments, 30 qualified resulting in 13 subjects in the high dose and 17 in the low dose group. 1 patient was lost to follow-up soon after treatment. 1 subject in the low-dose group underwent standard lobectomy after not being seizure-free 24 months following treatment. 1 subject experienced papilledema that responded partially to dexamethasone and underwent temporal lobectomy. Reductions in seizure frequency were seen in the high-dose group at 3, 6, 15, 18, and 24 months and for the low-dose group at 12, 15, 18, and 24 months (Wilcoxon signed rank test). Thus, both groups showed significant reductions in seizures at approximately one year following treatment. The low-dose group showed a seizure-free response at 24 months of [sim] 60% and the high-dose group response was [sim] 80% at 24 months. Although there is a difference in the seizure-free rates for the two treatment groups, the Fisher[apos]s Exact Test using a 2-sided p value indicates that the difference in percentage seizure-free for the two groups is not statistically significant (p=0.1194), a conclusion limited by the low power to resolve differences between treatment groups. Rates of steroid treatment, new headaches, and visual field defects did not differ between dose or seizure-outcome groups., GKS may offer a safe and effective alternative to standard open surgery for unilateral MTLE. High-dose GKS may be more effective than low-dose without additional morbidity. Disadvantages of GKS include latency to seizure-freedom. Further work is required to determine which patients may benefit from GKS., (Supported by NIH R01 NS039280; Elekta AB (Stockholm, Sweden).)
Clinical Epilepsy